PL446816A1 - Positively charged bilosomes and method of producing them - Google Patents

Positively charged bilosomes and method of producing them

Info

Publication number
PL446816A1
PL446816A1 PL446816A PL44681623A PL446816A1 PL 446816 A1 PL446816 A1 PL 446816A1 PL 446816 A PL446816 A PL 446816A PL 44681623 A PL44681623 A PL 44681623A PL 446816 A1 PL446816 A1 PL 446816A1
Authority
PL
Poland
Prior art keywords
bilosomes
positively charged
phosphoethanolamino
peg2000
dspe
Prior art date
Application number
PL446816A
Other languages
Polish (pl)
Other versions
PL248770B1 (en
Inventor
Urszula Bazylińska
Ewelina Waglewska
Original Assignee
Politechnika Wrocławska
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Politechnika Wrocławska filed Critical Politechnika Wrocławska
Priority to PL446816A priority Critical patent/PL248770B1/en
Publication of PL446816A1 publication Critical patent/PL446816A1/en
Publication of PL248770B1 publication Critical patent/PL248770B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Birds (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)

Abstract

Zgłoszenie ujawnia nowej generacji bilosomy o dodatnim ładunku, których otoczka składa się z fosfatydylocholiny z żółtek jaja kurzego (PC), chlorku 1,2-dioleoilo-3-trimetyloamoniopropanu (DOTAP-Cl) oraz hydratu cholanu sodu (SC), z możliwością utworzenia dodatkowej bariery sterycznej za pomocą 1,2-distearoilo-sn-glicero-fosfoetanoloamino-N-[metoksy(glikolu polietylenowego) 2000] (DSPE-PEG2000), przeznaczonych do stosowania w przemyśle medycznym, farmaceutycznym i kosmetycznym, jako nanonośniki substancji aktywnych biologicznie o różnej rozpuszczalności. Zgłoszenie zapewnia również sposób wytwarzania bilosomów o ładunku dodatnim charakteryzujący się tym, iż w pierwszej kolejności dokładnie odważone ilości fosfatydylocholiny z żółtek jaja kurzego (PC) (9-18 mg), chlorku 1,2-dioleoilo-3-trimetyloamoniopropanu (DOTAP-Cl) (12-21 mg) oraz 1,2-distearoilo-sn-glicero-fosfoetanoloamino-N-[metoksy(glikolu polietylenowego) 2000] (DSPE-PEG2000) (0-1,5 mg) rozpuszcza się w 3 ml chloroformu w kolbie okrągłodennej o pojemności 10 ml. Następnie rozpuszczalnik organiczny całkowicie odparowuje się pod zmniejszonym ciśnieniem w temperaturze 45°C za pomocą wyparki rotacyjnej (prędkość obrotowa: 80 rpm), aż do uzyskania cienkiej i całkowicie suchej warstwy lipidowej. Równomiernie utworzony na ściankach kolby okrągłodennej suchy film lipidowy uwadnia się kolejno w 3 ml wodnego roztworu zawierającego sól kwasu żółciowego - cholan sodu (SC) w stężeniu 1 mg/ml. Powstałą dyspersję miesza się przez 3 godziny na mieszadle magnetycznym w celu wytworzenia heterogenicznej populacji pęcherzyków. Na koniec dyspersję bilosomalną poddaje się sonifikacji w łaźni ultradźwiękowej, w wyniku czego otrzymuje się populacje małych jednowarstwowych pęcherzyków, które przechowuje się w temperaturze 4°C do ich późniejszego wykorzystania.The application discloses new generation positively charged bilosomes, the shell of which consists of egg yolk phosphatidylcholine (PC), 1,2-dioleoyl-3-trimethylammoniopropane chloride (DOTAP-Cl) and sodium cholate hydrate (SC), with the possibility of creating an additional steric barrier using 1,2-distearoyl-sn-glycero-phosphoethanolamino-N-[methoxy(polyethylene glycol) 2000] (DSPE-PEG2000), intended for use in the medical, pharmaceutical and cosmetic industries as nanocarriers of biologically active substances of various solubility. The application also provides a method for producing positively charged bilosomes characterized in that, first, precisely weighed amounts of egg yolk phosphatidylcholine (PC) (9-18 mg), 1,2-dioleoyl-3-trimethylammoniopropane chloride (DOTAP-Cl) (12-21 mg) and 1,2-distearoyl-sn-glycero-phosphoethanolamino-N-[methoxy(polyethylene glycol) 2000] (DSPE-PEG2000) (0-1.5 mg) are dissolved in 3 ml of chloroform in a 10 ml round-bottom flask. Then, the organic solvent is completely evaporated under reduced pressure at 45°C using a rotary evaporator (rotational speed: 80 rpm) until a thin and completely dry lipid layer is obtained. The dry lipid film uniformly formed on the walls of a round-bottom flask is hydrated successively in 3 ml of an aqueous solution containing the bile salt sodium cholate (SC) at a concentration of 1 mg/ml. The resulting dispersion is stirred for 3 hours on a magnetic stirrer to generate a heterogeneous population of vesicles. Finally, the bilosomal dispersion is sonicated in an ultrasonic bath, resulting in populations of small unilamellar vesicles that are stored at 4°C until later use.

PL446816A 2023-11-23 2023-11-23 Positively charged bilosomes and method of producing them PL248770B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL446816A PL248770B1 (en) 2023-11-23 2023-11-23 Positively charged bilosomes and method of producing them

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL446816A PL248770B1 (en) 2023-11-23 2023-11-23 Positively charged bilosomes and method of producing them

Publications (2)

Publication Number Publication Date
PL446816A1 true PL446816A1 (en) 2025-05-26
PL248770B1 PL248770B1 (en) 2026-01-26

Family

ID=95821465

Family Applications (1)

Application Number Title Priority Date Filing Date
PL446816A PL248770B1 (en) 2023-11-23 2023-11-23 Positively charged bilosomes and method of producing them

Country Status (1)

Country Link
PL (1) PL248770B1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020252375A1 (en) * 2019-06-14 2020-12-17 Dnalite Therapeutics, Inc. Compositions and methods for biological delivery vehicles
CN112773905A (en) * 2021-02-08 2021-05-11 暨南大学 Macrophage backpack system and preparation method and application thereof
WO2023012722A1 (en) * 2021-08-06 2023-02-09 Leadermed Champion Limited miRNA-BASED COMPOSITIONS AND METHODS OF USE THEREOF

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020252375A1 (en) * 2019-06-14 2020-12-17 Dnalite Therapeutics, Inc. Compositions and methods for biological delivery vehicles
CN112773905A (en) * 2021-02-08 2021-05-11 暨南大学 Macrophage backpack system and preparation method and application thereof
WO2023012722A1 (en) * 2021-08-06 2023-02-09 Leadermed Champion Limited miRNA-BASED COMPOSITIONS AND METHODS OF USE THEREOF

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WAGLEWSKA E, PUCEK-KACZMAREK A, BAZYLIŃSKA U.: "Colloids Surf B Biointerfaces. 2022 Jul;215:112524", SELF-ASSEMBLED BILOSOMES WITH STIMULI-RESPONSIVE PROPERTIES AS BIOINSPIRED DUAL-TUNABLE NANOPLATFORM FOR PH/TEMPERATURE-TRIGGERED RELEASE OF HYBRID CARGO, DOI: 10.1016/j.colsurfb.2022.112524 *

Also Published As

Publication number Publication date
PL248770B1 (en) 2026-01-26

Similar Documents

Publication Publication Date Title
TW436295B (en) Concentrated aqueous solutions of argatroban
US7473432B2 (en) NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
CA1144480A (en) Stabilized parenterally administrable solutions
Hortelão et al. LipoBots: Using liposomal vesicles as protective shell of urease‐based nanomotors
FI110842B (en) Process for the preparation of a pharmaceutical composition containing a defined lipid system
DE60318227T2 (en) AGGREGATES WITH INCREASED DEFORMABILITY, CONSISTING OF AT LEAST THREE AMPHIPHILES, FOR IMPROVED TRANSPORT BY PIVOTABLE BARRIERS AND FOR NON-INVERSIVE ADMINISTRATION OF VIVO MEDICAMENTS, IN PARTICULAR THROUGH THE SKIN
CN101466357A (en) Direct cellular energy delivery system
JPH01160915A (en) Improved preparation method for amphotericin B liposomes
WO2011129588A2 (en) Polymer/liposome nanocomposite composition for percutaneous absorption, and method for preparing same
Gualdrón-López et al. Translocation of solutes and proteins across the glycosomal membrane of trypanosomes; possibilities and limitations for targeting with trypanocidal drugs
MX2011000932A (en) Methods of administering topical antifungal formulations for the treatment of fungal infections.
SG176297A1 (en) Formulations for the treatment of deep tissue pain
MX2014012198A (en) Vesicular formulations for use in the treatment of pain or reduced mobility of a joint.
Li et al. Electrostatically entrapped colistin liposomes for the treatment of Pseudomonas aeruginosa infection
PL446816A1 (en) Positively charged bilosomes and method of producing them
US20030013763A1 (en) Glycerol-lactate esters for use as an energy supplement during exercise and recovery
Patel et al. Preparation and formulation of transferosomes containing an antifungal agent for transdermal delivery: Application of Plackett-Burman design to identify significant factors influencing vesicle size
Van Deenen Permeability and topography of membranes
CN110250495B (en) A kind of Vc liposome hydrogel and preparation method thereof
CN103140587B (en) Compositions and manufacture method thereof containing 2-acyl group-hemolytic phosphatidylserine
CA2919971A1 (en) Vesicular formulations for topical administration
CN102614515A (en) Novel chemical restructuring high-density lipoprotein drug carrying system with targeted and double anti-tumor effects and application
CN104349782A (en) Vesicular formulations
JP2009521400A (en) Oral joint function improvement and protective agent containing hyaluronic acid phospholipid compound
US20050095283A1 (en) Compositions and methods for topically treating diseases